ClinicalTrialsFinder
RecruitingPhase 2NCT07437560

Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Melanotan II (Synthetic Cyclic Melanocortin Receptor Agonist) as an Adjunct to Narrowband UV-B Phototherapy in Adults With Stable Nonsegmental Vitiligo

Sponsor

Hudson Biotech

Enrollment

60 participants

Start Date

Feb 2, 2026

Study Type

INTERVENTIONAL

Conditions

NonSegmental VitiligoNonsegmental Vitiligo (Stable)

Summary

This example interventional study record describes a randomized Phase 2 clinical trial evaluating investigational Melanotan II (MT-II) as an adjunct to standard NB-UVB phototherapy for repigmentation in adults with stable nonsegmental vitiligo.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Melanotan II (MT-II), a procedure called Narrowband UV-B (NB-UVB) phototherapy, and others for people with nonsegmental vitiligo and nonsegmental vitiligo (stable). The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMelanotan II (MT-II)

administered per protocol

DRUGPlacebo

matched, administered per protocol.

PROCEDURENarrowband UV-B (NB-UVB) phototherapy

standardized schedule per site protocol

Locations(1)

Peking University Shenzhen Hospital

Shenzhen, Guangdong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07437560

Related Trials

A Study of Zasocitinib in Adults With Nonsegmental Vitiligo

NCT0710828370 locations

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo

NCT0654836098 locations

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo

NCT0680481179 locations